Related references
Note: Only part of the references are listed.Diagnostic pathology of early systemic cancer: ERBB2 gene amplification in single disseminated cancer cells determines patient survival in operable esophageal cancer
Martin Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer
Yang-Kun Wang et al.
CANCER BIOMARKERS (2018)
EGFR High Expression, but not KRAS Status, Predicts Sensitivity of Pancreatic Cancer Cells to Nimotuzumab Treatment In Vivo
Chenfei Zhou et al.
CURRENT CANCER DRUG TARGETS (2017)
The neXtProt knowledgebase on human proteins: 2017 update
Pascale Gaudet et al.
NUCLEIC ACIDS RESEARCH (2017)
EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer
Sajid A. Khan et al.
PATHOLOGY & ONCOLOGY RESEARCH (2017)
KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma
Jonas Cicenas et al.
MEDICAL ONCOLOGY (2017)
Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression
Daniela Alterio et al.
MEDICAL ONCOLOGY (2017)
Comparison of the c-MET gene amplification between primary tumor and metastatic lymph nodes in non-small cell lung cancer
Chun-wei Xu et al.
THORACIC CANCER (2017)
EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
Sarah R. Sabir et al.
CANCERS (2017)
Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas
Bruno Vincenzi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
Shigenari Nukaga et al.
CANCER RESEARCH (2017)
Akt2 and p-Akt overexpression in oral cancer cells is due to a reduced rate of protein degradation
Prakasit Archewa et al.
JOURNAL OF INVESTIGATIVE AND CLINICAL DENTISTRY (2017)
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications
Helen Gharwan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The Aurora kinase inhibitors in cancer research and therapy
Jonas Cicenas
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Multi-kinase inhibitors, AURKs and cancer
Jonas Cicenas et al.
MEDICAL ONCOLOGY (2016)
Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program
Adrienne L. Morey et al.
PATHOLOGY (2016)
Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients
Paola Griseri et al.
ONCOTARGET (2016)
Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion
Nakho Chang et al.
ONCOTARGET (2016)
Emerging treatment for advanced lung cancer with EGFR mutation
Cengiz Inal et al.
EXPERT OPINION ON EMERGING DRUGS (2015)
BRAF V600E mutation-specific antibody: A review
Lauren L. Ritterhouse et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2015)
Clinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: a systematic review and meta-analysis
Lin Yan et al.
SCIENTIFIC REPORTS (2015)
Targeted Therapies in Non-Small Cell Lung Cance-rBeyond EGFR and ALK
Sacha I. Rothschild
CANCERS (2015)
MET Amplification Is Not Rare and Predicts Unfavorable Clinical Outcomes in Patients With Recurrent/Metastatic Gastric Cancer After Chemotherapy
Xin An et al.
CANCER (2014)
Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer
Xin-Juan Fan et al.
TUMOR BIOLOGY (2014)
Highlights of the Latest Advances in Research on CDK Inhibitors
Jonas Cicenas et al.
CANCERS (2014)
Androgen receptor phosphorylation at serine 515 by Cdk1 predicts biochemical relapse in prostate cancer patients
J. M. Willder et al.
BRITISH JOURNAL OF CANCER (2013)
Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients
Futao Hou et al.
MEDICAL ONCOLOGY (2012)
The CDK inhibitors in cancer research and therapy
Jonas Cicenas et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2011)
Pharmacokinetic and-Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab
Bing-Bing Yang et al.
CLINICAL PHARMACOKINETICS (2010)
HER2 gene amplification in primary mucinous ovarian cancer: a potential therapeutic target
Chih-Ping Han et al.
HISTOPATHOLOGY (2010)
Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer
De-Yuan Fu et al.
HUMAN PATHOLOGY (2010)
Increased Level of Phosphorylated ShcA Measured by Chemiluminescence-Linked Immunoassay Is a Predictor of Good Prognosis in Primary Breast Cancer Expressing Low Levels of Estrogen Receptor
Jonas Cicenas et al.
Cancers (2010)
Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer
Giuseppe Curigliano et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Epigenetic inactivation of checkpoint kinase 2 gene in non-small cell lung cancer and its relationship with clinicopathological features
Dong Sun Kim et al.
LUNG CANCER (2009)
BRAFV600E mutation and outcome of patients with papillary thyroid carcinoma:: A 15-year median follow-up study
Rossella Elisei et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias
J. Gotlib et al.
LEUKEMIA (2008)
Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion
Mirang Kim et al.
CARCINOGENESIS (2008)
The potential role of Akt phosphorylation in human cancers
J. Cicenas
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2008)
Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: Immunohistochemistry and chromogenic in situ hybridization
Eun Y. Cho et al.
PATHOLOGY INTERNATIONAL (2008)
Constitutive Phosphorylation of Aurora-A on Ser51 Induces Its Stabilization and Consequent Overexpression in Cancer
Shojiro Kitajima et al.
PLOS ONE (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The potential role of the EGFR/ERBB2 heterodimer in breast cancer
Jonas Cicenas
EXPERT OPINION ON THERAPEUTIC PATENTS (2007)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation
Hitoshi Kiyoi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2006)
Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients
J Cicenas et al.
EUROPEAN JOURNAL OF CANCER (2006)
Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer
K Milde-Langosch et al.
BRITISH JOURNAL OF CANCER (2005)
Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients
MP DiGiovanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2
J Cicenas et al.
BREAST CANCER RESEARCH (2005)
Phosphorylation/cytoplasmic localization of p2lCip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients
WY Xia et al.
CLINICAL CANCER RESEARCH (2004)
Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients
T Kanematsu et al.
ONCOLOGY RESEARCH (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
ST1571 (Gleevec (TM)) as a paradigm for cancer therapy
BJ Druker
TRENDS IN MOLECULAR MEDICINE (2002)
Share Paper
